Robert W. Baird Upgrades Edwards Lifesciences (NYSE:EW) to “Outperform”

Edwards Lifesciences (NYSE:EW) was upgraded by equities researchers at Robert W. Baird from a “neutral” rating to an “outperform” rating in a note issued to investors on Thursday, Briefing.com reports. The brokerage currently has a $116.00 price objective on the medical research company’s stock. Robert W. Baird‘s price target suggests a potential upside of 16.72% from the stock’s previous close.

A number of other brokerages also recently commented on EW. Sanford C. Bernstein boosted their target price on shares of Edwards Lifesciences from $96.00 to $99.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Jefferies Financial Group boosted their target price on Edwards Lifesciences from $102.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Rothschild & Co Redburn increased their price target on Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Piper Sandler reiterated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, The Goldman Sachs Group upped their target price on Edwards Lifesciences from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.08.

Edwards Lifesciences Price Performance

EW opened at $99.39 on Thursday. Edwards Lifesciences has a 12-month low of $74.66 and a 12-month high of $100.25. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $88.48 and its 200-day simple moving average is $85.61. The company has a market capitalization of $57.23 billion, a price-to-earnings ratio of 57.12, a PEG ratio of 2.49 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 5,045 shares of company stock valued at $451,596. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the second quarter worth $5,318,092,000. Bank of New York Mellon Corp purchased a new position in Edwards Lifesciences in the second quarter valued at $1,274,082,000. Bank of America Corp DE purchased a new position in Edwards Lifesciences in the second quarter valued at $605,397,000. Deutsche Bank AG purchased a new position in Edwards Lifesciences in the second quarter valued at $516,552,000. Finally, Legal & General Group Plc acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $389,089,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, topping the $0.74 consensus, and revenue of $1.72 billion versus expectations of $1.68 billion. Revenue grew year over year, while the company raised its full-year outlook and narrowed its 2026 forecast range. Q3 earnings, revenue and outlook
• Positive Sentiment: Truist Financial upgraded EW from “hold” to “strong-buy,” adding analyst support. Truist upgrade
• Positive Sentiment: Management highlighted strong momentum in its transcatheter mitral and tricuspid therapies business, with TMTT sales up 44%. Separately, trial results for the PASCAL tricuspid repair system showed better outcomes than medical therapy through one year, supporting the product’s potential. Q3 results and TMTT growth PASCAL trial results
• Negative Sentiment: CEO commentary acknowledged that more TAVR competition is coming, which could pressure Edwards’ position in a key market. RBC also said the Progress trial data is unlikely to meaningfully expand the transcatheter market, limiting the potential upside from that study. TAVR competition RBC assessment of Progress trial

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.